Geneva Biotech is a privately held biotechnology company, based in Geneva, Switzerland. Founded in 2012

Geneva Biotech ManuBac™

Intelligent DNA delivery systems

Welcome Guest \\ Login


Technology Description

ManuBac™ : Virion Free Protein Production 

Baculovirus is a leading methodology for producing virus like particle (VLP) vaccines. Traditional baculovirus expression systems co-produce baculovirus virions together with the VLP. Separation of VLPs from contaminating virions is costly, and adds an additional regulatory risk in the development of biopharmaceuticals. ManuBac™ solves this problem by allowing virion-free VLP production. 

ManuBac™ is under development and will be available in 2017.

Schematic Diagram of ManuBac Expression System

ManuBac™ vs. Traditional Baculovirus Production of VLPs. During traditional production of VLPs using baculovirus (top), virions (blue dots) are produced together with the VLP (red dots). ManuBac™ (bottom) takes advantage of iBac™ induction switches to turn off production of baculovirions at the same time VLP production is turned on.


E.coli cell expression

Research Highlights

our r&dView all

Latest News

LARGE DNA CARGO GENOME ENGINEERING PROJECTGeneva Biotech and Sphere Fluidics launch R&D project to develop methods that enable large DNA cargo delivery and genome ...

View all

Contact Us